Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
247 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Epilepsy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2014', provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Epilepsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Epilepsy Overview 9 Therapeutics Development 10 Pipeline Products for Epilepsy - Overview 10 Pipeline Products for Epilepsy - Comparative Analysis 11 Epilepsy - Therapeutics under Development by Companies 12 Epilepsy - Therapeutics under Investigation by Universities/Institutes 17 Epilepsy - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Epilepsy - Products under Development by Companies 22 Epilepsy - Products under Investigation by Universities/Institutes 26 Epilepsy - Companies Involved in Therapeutics Development 27 Allergan, Inc. 27 Neurocrine Biosciences, Inc. 28 Novartis AG 29 Acorda Therapeutics, Inc. 30 Astellas Pharma Inc. 31 Chong Kun Dang Pharmaceutical Corp. 32 Eisai Co., Ltd. 33 H. Lundbeck A/S 34 Pfizer Inc. 35 UCB S.A. 36 Aeolus Pharmaceuticals, Inc. 37 GW Pharmaceuticals plc 38 Anavex Life Sciences Corp. 39 Bionomics Limited 40 Paloma Pharmaceuticals, Inc. 41 D-Pharm Ltd. 42 VistaGen Therapeutics , Inc. 43 INSYS Therapeutics, Inc. 44 Upsher-Smith Laboratories, Inc. 45 Snowdon Inc. 46 Lipicard Technologies Limited 47 MedGenesis Therapeutix Inc. 48 Celentyx Ltd. 49 Adamas Pharmaceuticals, Inc. 50 Concert Pharmaceuticals, Inc. 51 Knopp Biosciences LLC 52 Biovista Inc. 53 Asklepios BioPharmaceutical, Inc. 54 Marinus Pharmaceuticals, Inc. 55 Bial - Portela & Ca, S.A. 56 Lohocla Research Corporation 57 Desitin Arzneimittel GmbH 58 Vichem Chemie Research Ltd. 59 MarcoPolo Pharmaceuticals SA 60 Aestus Therapeutics, Inc. 61 Convergence Pharmaceuticals Ltd. 62 BioCrea GmbH 63 Advicenne Pharma 64 SciFluor Life Sciences, LLC 65 Epirus Biopharmaceuticals, Inc. 66 Glialogix, Inc. 67 Epilepsy - Therapeutics Assessment 68 Assessment by Monotherapy Products 68 Assessment by Target 69 Assessment by Mechanism of Action 73 Assessment by Route of Administration 78 Assessment by Molecule Type 80 Drug Profiles 82 lacosamide - Drug Profile 82 perampanel - Drug Profile 86 carbamazepine - Drug Profile 88 levetiracetam - Drug Profile 90 ADV-5803 - Drug Profile 91 diazepam - Drug Profile 92 lacosamide - Drug Profile 94 brivaracetam - Drug Profile 98 diazepam - Drug Profile 100 eslicarbazepine acetate - Drug Profile 101 lacosamide - Drug Profile 104 everolimus - Drug Profile 108 naluzotan - Drug Profile 112 DP-VPA - Drug Profile 113 ganaxolone - Drug Profile 115 VLB-01 - Drug Profile 117 topiramate - Drug Profile 118 CX-1010 - Drug Profile 119 tonabersat - Drug Profile 120 GWP-42006 - Drug Profile 121 AV-101 - Drug Profile 122 INS-001 - Drug Profile 124 PF-04895162 - Drug Profile 125 ADV-6770 - Drug Profile 126 CKD-903 - Drug Profile 127 ANAVEX-2-73 - Drug Profile 128 Small Molecules for CNS Disorders - Drug Profile 129 ANAVEX-19-144 - Drug Profile 130 P-529 - Drug Profile 131 DP-VPA - Drug Profile 133 liatermin - Drug Profile 135 BVA-601 - Drug Profile 138 Small Molecules for Neurological Disorders - Drug Profile 139 AEOL-11207 - Drug Profile 140 C-10068 - Drug Profile 141 Z-944 - Drug Profile 142 Drug for Epilepsy - Drug Profile 143 VID-45110 - Drug Profile 144 BNP-TLE - Drug Profile 145 SL-327 - Drug Profile 146 Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 147 Drug to Activate GABA Receptor for Epilepsy - Drug Profile 148 KM-314 - Drug Profile 149 KM-113 - Drug Profile 150 SF-0034 - Drug Profile 151 2-DG - Drug Profile 152 ADV-6769 - Drug Profile 154 LT-4121 - Drug Profile 155 LT-4122 - Drug Profile 156 LT-4123 - Drug Profile 157 LT-4124 - Drug Profile 158 LT-4125 - Drug Profile 159 LT-4126 - Drug Profile 160 MRS-5474 - Drug Profile 161 GLX-1112 - Drug Profile 162 Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 163 Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile 164 Small Molecules to Inhibit NMDA Receptor and GABAA Receptor for CNS - Drug Profile 165 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 166 MSP - Drug Profile 167 ESB - Drug Profile 168 EMSP - Drug Profile 169 ESBB - Drug Profile 170 SCT-66 - Drug Profile 171 VAD-1 - Drug Profile 172 VAD-2 - Drug Profile 173 VU-0456810 - Drug Profile 174 CNV-1061436 - Drug Profile 175 Cannabidiol - Drug Profile 176 FV-082 - Drug Profile 177 FV-137 - Drug Profile 178 Small Molecule to Inhibit Sodium Channel for Epilepsy - Drug Profile 179 Small Molecules for Epilepsy - Drug Profile 180 Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 182 VB-3323 - Drug Profile 183 Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 184 Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 185 Small Molecule for Central Nervous System - Drug Profile 186 AEOL-1114B - Drug Profile 188 AEOL-11203 - Drug Profile 189 AVL-5189 - Drug Profile 190 Cell Therapy for Neurological Disorders - Drug Profile 191 Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 192 Gene Therapy for Epilepsy - Drug Profile 193 UBP-608 - Drug Profile 194 Small Molecules to Block Kir Channel for Cardiovascular and CNS - Drug Profile 195 PRTT-200 - Drug Profile 196 IPR-003 - Drug Profile 197 Small Molecule to Target mGluR5 and mGluR6 for Neurological Disorders - Drug Profile 198 ADS-8800 Series - Drug Profile 199 Epilepsy - Recent Pipeline Updates 200 Epilepsy - Dormant Projects 227 Epilepsy - Discontinued Products 231 Epilepsy - Product Development Milestones 232 Featured News & Press Releases 232 Appendix 239 Methodology 239 Coverage 239 Secondary Research 239 Primary Research 239 Expert Panel Validation 239 Contact Us 240 Disclaimer 240
List of Tables Number of Products under Development for Epilepsy, H2 2014 17 Number of Products under Development for Epilepsy - Comparative Analysis, H2 2014 18 Number of Products under Development by Companies, H2 2014 20 Number of Products under Development by Companies, H2 2014 (Contd..1) 21 Number of Products under Development by Companies, H2 2014 (Contd..2) 22 Number of Products under Development by Companies, H2 2014 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2014 25 Comparative Analysis by Late Stage Development, H2 2014 26 Comparative Analysis by Clinical Stage Development, H2 2014 27 Comparative Analysis by Early Stage Development, H2 2014 28 Products under Development by Companies, H2 2014 29 Products under Development by Companies, H2 2014 (Contd..1) 30 Products under Development by Companies, H2 2014 (Contd..2) 31 Products under Development by Companies, H2 2014 (Contd..3) 32 Products under Investigation by Universities/Institutes, H2 2014 33 Epilepsy - Pipeline by Allergan, Inc., H2 2014 34 Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H2 2014 35 Epilepsy - Pipeline by Novartis AG, H2 2014 36 Epilepsy - Pipeline by Acorda Therapeutics, Inc., H2 2014 37 Epilepsy - Pipeline by Astellas Pharma Inc., H2 2014 38 Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 39 Epilepsy - Pipeline by Eisai Co., Ltd., H2 2014 40 Epilepsy - Pipeline by H. Lundbeck A/S, H2 2014 41 Epilepsy - Pipeline by Pfizer Inc., H2 2014 42 Epilepsy - Pipeline by UCB S.A., H2 2014 43 Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2014 44 Epilepsy - Pipeline by GW Pharmaceuticals plc, H2 2014 45 Epilepsy - Pipeline by Anavex Life Sciences Corp., H2 2014 46 Epilepsy - Pipeline by Bionomics Limited, H2 2014 47 Epilepsy - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 48 Epilepsy - Pipeline by D-Pharm Ltd., H2 2014 49 Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H2 2014 50 Epilepsy - Pipeline by INSYS Therapeutics, Inc., H2 2014 51 Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 52 Epilepsy - Pipeline by Snowdon Inc., H2 2014 53 Epilepsy - Pipeline by Lipicard Technologies Limited, H2 2014 54 Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H2 2014 55 Epilepsy - Pipeline by Celentyx Ltd., H2 2014 56 Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 57 Epilepsy - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 58 Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2014 59 Epilepsy - Pipeline by Biovista Inc., H2 2014 60 Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2014 61 Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H2 2014 62 Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H2 2014 63 Epilepsy - Pipeline by Lohocla Research Corporation, H2 2014 64 Epilepsy - Pipeline by Desitin Arzneimittel GmbH, H2 2014 65 Epilepsy - Pipeline by Vichem Chemie Research Ltd., H2 2014 66 Epilepsy - Pipeline by MarcoPolo Pharmaceuticals SA, H2 2014 67 Epilepsy - Pipeline by Aestus Therapeutics, Inc., H2 2014 68 Epilepsy - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 69 Epilepsy - Pipeline by BioCrea GmbH, H2 2014 70 Epilepsy - Pipeline by Advicenne Pharma, H2 2014 71 Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H2 2014 72 Epilepsy - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 73 Epilepsy - Pipeline by Glialogix, Inc., H2 2014 74 Assessment by Monotherapy Products, H2 2014 75 Number of Products by Stage and Target, H2 2014 78 Number of Products by Stage and Mechanism of Action, H2 2014 82 Number of Products by Stage and Route of Administration, H2 2014 86 Number of Products by Stage and Molecule Type, H2 2014 88 Epilepsy Therapeutics - Recent Pipeline Updates, H2 2014 207 Epilepsy - Dormant Projects, H2 2014 234 Epilepsy - Dormant Projects (Contd..1), H2 2014 235 Epilepsy - Dormant Projects (Contd..2), H2 2014 236 Epilepsy - Dormant Projects (Contd..3), H2 2014 237 Epilepsy - Discontinued Products, H2 2014 238
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
